Neumora Therapeutics (NMRA) Change in Accured Expenses (2022 - 2026)

Neumora Therapeutics' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 339.43% year-over-year to -$4.0 million in Q1 2026; TTM through Mar 2026 was -$1.5 million, a 111.54% decrease from a year earlier, with the FY2025 full-year figure at $4.2 million, down 42.03% from the prior year.
• Change in Accured Expenses declined to -$4.0 million in Q1 2026 per NMRA's latest filing, from $4.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $7.6 million in Q3 2024 and bottomed at -$6.3 million in Q2 2025.
• The 5-year median for Change in Accured Expenses is $1.9 million (2024), against an average of $1.5 million.
• Biggest YoY gain for Change in Accured Expenses was 184.95% in 2024; the steepest drop was 458.83% in 2024.
• Year by year, Change in Accured Expenses stood at $7.0 million in 2022, then plunged by 130.73% to -$2.2 million in 2023, then soared by 184.95% to $1.8 million in 2024, then surged by 116.89% to $4.0 million in 2025, then tumbled by 201.01% to -$4.0 million in 2026.
• Per Business Quant, the three latest NMRA Change in Accured Expenses figures stand at -$4.0 million (Q1 2026), $4.0 million (Q4 2025), and $4.9 million (Q3 2025).